On September 10, we learned from Novo Nordisk that its long-acting growth hormone passy growth hormone injection has been approved for three new pediatric indications. They are children aged 2.5 and above who treat growth retardation associated with Noonan syndrome, children aged 2.5 and above who are idiopathically short, and children aged 2.5 and above who were born younger than gestational age and were unable to keep up with their growth and were short at age 2. Previously, the drug had been approved domestically to treat growth hormone deficiency in children.

On September 10, we learned from Novo Nordisk that its long-acting growth hormone passy growth hormone injection has been approved for three new pediatric indications. They are children aged 2.5 and above who treat growth retardation associated with Noonan syndrome, children aged 2.5 and above who are idiopathically short, and children aged 2.5 and above who were born younger than gestational age and were unable to keep up with their growth and were short at age 2. Previously, the drug had been approved domestically to treat growth hormone deficiency in children.